These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4041311)

  • 1. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). European MH Group.
    Br J Anaesth; 1985 Oct; 57(10):1038. PubMed ID: 4041311
    [No Abstract]   [Full Text] [Related]  

  • 2. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
    Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
    Ellis FR; Halsall PJ; Hopkins PM
    Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
    Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
    PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Static v. dynamic tests in the in vitro diagnosis of malignant hyperthermia susceptibility.
    Ranklev E; Fletcher R; Blomquist S
    Br J Anaesth; 1986 Jun; 58(6):646-8. PubMed ID: 3707802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcalorimetric studies in malignant hyperpyrexia susceptible individuals.
    Ranklev E; Monti M; Fletcher R
    Br J Anaesth; 1985 Oct; 57(10):991-3. PubMed ID: 4041326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
    Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Adamantidis MM; Reyford GH; Imbenotte M; Cordonnier C
    Br J Anaesth; 1990 Dec; 65(6):791-5. PubMed ID: 1702303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of malignant hyperthermia in Denmark and Sweden.
    Ording H; Ranklev E; Fletcher R
    Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
    Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
    Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis of susceptibility to malignant hyperthermia in children].
    Krivosic-Horber R; Adnet P; Krivosic I; Reyford H
    Arch Fr Pediatr; 1990; 47(6):421-4. PubMed ID: 2403268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of malignant hyperthermia in Sweden.
    Ranklev E; Fletcher R
    Acta Anaesthesiol Scand; 1986 Nov; 30(8):693-6. PubMed ID: 3811813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
    Britt BA; Scott EA
    Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs.
    Schuster F; Schöll H; Hager M; Müller R; Roewer N; Anetseder M
    Anesth Analg; 2006 Feb; 102(2):468-72. PubMed ID: 16428544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of spin resonance spectroscopy of red blood cell membranes to detect malignant hyperthermia susceptibility.
    Halsall PJ; Ellis FR; Knowles PF
    Br J Anaesth; 1992 Nov; 69(5):471-3. PubMed ID: 1334685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.